Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Hepatitis B surface antigen (HBsAg), core total antibody (anti-HBc) and surface antibody (anti-HBs) were detected by the Architect immunoassay (Abbott Diagnostics, Germany). Hepatitis B infection was ...

Department of Thoracic Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The second Affiliated Hospital of Nanchang Medical College, Nanchang, China ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus ... either positive for the HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc).

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear hepatitis ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

For patients at high risk of hepatitis B reactivation, AGA recommends preventive antiviral medication. Reactivated HBV can lead to liver damage, hospitalization, and even death.

Also referred to as BJT-778, brelovitug targets the hepatitis B virus’ surface antigen. The antibody neutralises and eliminates hepatitis B and D virions, as well as depleting HBsAg-containing ...

Brelovitug, a fully human immunoglobulin G1 monoclonal antibody that targets the surface antigen of the hepatitis B virus, has previously received Orphan and PRIME designation from the European ...